Stock screener

AVTX

Conviction 90HealthcareScan · Mon, Jul 20, 2026
AVTX$18.22-5.94%
ResistanceSupportVol 14Insider sell
63 bars
16
Vol MA14 1.49M
Apr 20May 6May 26Jun 11Jul 1Jul 20
Avalo Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.avalotx.com
Price18.22
Change-5.94%
Gap+0.13%
Rel volume1.91×
Avg volume1.93M
Avg $ vol35.48M
SMA 2018.61
SMA 5017.11
SMA 20016.30
Price vs 50+6.52%
Price vs 200+11.81%
MA stackbullish
50/200 cross
Supertrendup · 15.82
RSI (14)52
MACD hist-0.14
MACD crossbear · 3d
Stoch %K / %D29 / 37
ADX (14)21
+DI / −DI22 / 16
RSI divergence
MACD divergence
ATR %+7.26%
ADR %7.47%
52w high22.87
52w low6.25
From 52w high-20.33%
Above 52w low+191.52%
New 52w highNo
SqueezeOff
Bollinger width16.73%
%B0.38
Donchian pos59.09%
Donchian high20.65
Donchian low14.71
AVWAP (52w high)17.50
vs AVWAP high+4.12%
AVWAP (52w low)16.61
vs AVWAP low+9.68%
OBV trendUp
Chaikin MF (20)0.02
Today vs 20d1.91×
Avg vol (14d)1.49M
Avg vol (20d)1.93M
Avg $ vol (20d)35.48M
Market cap957.74M
RS 3m (vs SPY)+28.39%
RS 6m (vs SPY)+11.97%
RS line new highNo
Trend template6/8
Technical rank80.8
1 week-3.65%
1 month+18.31%
3 months+26.26%
6 months+16.50%
1 year+221.91%
YTD+7.05%
P/E-12.24
P/B14.02
P/S
P/FCF-18.58
EPS-5.84
Div yield
ROE-114.55%
ROA-78.35%
Debt/Eq0.22
Current7.66
EV/EBITDA-13.06
Gross margin
Net margin
Rev growth-86.62%
EPS growth-122.78%
Price target44.90
Target upside146.43%
Analyst ratingBuy
Institutional61.67%
Ent. value948.06M
Revenue0
Net income-19.63M
Gross profit
Free cash flow-51.55M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out52.57M
Employees33
ListedFri, Nov 13, 2015
Free float21.22M
Float %86.6%
Short interest12.31M
Days to cover4.3d
Short volume83.5%
Squeeze score95 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.98 vs −$1.00
Last surprise+2.0% beat
Setup gradeA+
Conviction90 / 100
Pattern quality
Tech rank80.8 / 100
Group rank23 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance20.55
Support13.90
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in AVTX

All disclosures →
No recent disclosed trades by Congress in AVTX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in AVTX · 4 buys · 6 sells

InsiderSideShares
Doyle Mittie
Chief Medical Officer · Common Stock · 2026-06-23
Sell1.45K
Doyle Mittie
Chief Medical Officer · Common Stock · 2026-06-23
Exercise1.45K
Doyle Mittie
Chief Medical Officer · Stock Option (Right to Buy) · 2026-06-23
Exercise1.45K
Philip Ron M
Director · Stock Option (Right to Buy) · 2026-06-23
Grant40.2K
VARKI PAUL
Chief Legal Officer · Common Stock · 2026-06-10
Tax1.08K
Sullivan Christopher Ryan
Chief Financial Officer · Common Stock · 2026-06-10
Tax138
Doyle Mittie
Chief Medical Officer · Common Stock · 2026-06-10
Tax1.08K
Riley Jennifer
Chief Strategy Officer · Common Stock · 2026-06-10
Tax588
Jain Rita
Director · Stock Option (Right to Buy) · 2026-06-02
Grant20.1K
KANTOFF AARON
Director · Stock Option (Right to Buy) · 2026-06-02
Grant20.1K

SEC filings

EDGAR filings in AVTX · 9 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.